Nachrichten zur Atara Biotherapeutics Inc. Aktie

ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Atara Biotherapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ATRA

NEW YORK, April 18, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm,…

NEW YORK, April 06, 2026 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Atara Biotherapeutics, Inc.…

NEW YORK, March 25, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm,…

SAN DIEGO, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV) (Artiva), a clinical-stage biotechnology company…

Atara Biotherapeutics stock plunges after FDA rejects cancer therapy…

Atara Biotherapeutics (ATRA) saw its shares surge in the last session with trading volume being higher than average. The latest…

Atara Biotherapeutics (ATRA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to…

Atara Biotherapeutics (ATRA) delivered earnings and revenue surprises of 68.85% and 150.02%, respectively, for the quarter ended December 2024. Do…

The consensus price target hints at a 33% upside potential for Atara Biotherapeutics (ATRA). While empirical research shows that this…

…

Atara Biotherapeutics (ATRA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the companys earnings prospects.…

Atara Biotherapeutics (ATRA) delivered earnings and revenue surprises of -148% and 40.70%, respectively, for the quarter ended June 2024. Do…